Standard Biotools Capital Expenditures (CapEx) Growth & History (LAB)
Standard Biotools's capital expenditures (capex) was $8.3M for fiscal 2025.
View full Standard Biotools company overviewStandard Biotools annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.3M | −$52,000 | −0.62% |
| 2024 | 2024-12-31 | $8.4M | $5.5M | +195.13% |
| 2023 | 2023-12-31 | $2.8M | −$994,000 | −25.99% |
| 2022 | 2022-12-31 | $3.8M | −$9.4M | −71.16% |
| 2021 | 2021-12-31 | $13.3M | $547,000 | +4.30% |
| 2020 | 2020-12-31 | $12.7M | $10.2M | +402.45% |
| 2019 | 2019-12-31 | $2.5M | $2.2M | +580.38% |
| 2018 | 2018-12-31 | $372,000 | −$1.2M | −76.25% |
| 2017 | 2017-12-31 | $1.6M | −$3.5M | −69.08% |
| 2016 | 2016-12-31 | $5.1M | $1.1M | +27.20% |
| 2015 | 2015-12-31 | $4.0M | −$3.4M | −46.21% |
| 2014 | 2014-12-31 | $7.4M | $4.0M | +114.83% |
| 2013 | 2013-12-31 | $3.4M | $1.1M | +44.55% |
| 2012 | 2012-12-31 | $2.4M | $708,000 | +42.24% |
| 2011 | 2011-12-31 | $1.7M | $137,000 | +8.90% |
| 2010 | 2010-12-31 | $1.5M | $740,000 | +92.62% |
| 2009 | 2009-12-31 | $799,000 | — | — |
Standard Biotools quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $344,000 | −$1.5M | −81.77% |
| Q1 2026 | 2026-03-31 | $570,000 | −$4.5M | −88.72% |
| Q4 2025 | 2025-12-31 | $476,000 | −$2.9M | −85.93% |
| Q3 2025 | 2025-09-30 | $886,000 | −$1.4M | −60.71% |
| Q2 2025 | 2025-06-30 | $1.9M | −$50,000 | −2.58% |
| Q1 2025 | 2025-03-31 | $5.1M | $4.3M | +547.12% |
| Q4 2024 | 2024-12-31 | $3.4M | $3.3M | +4235.90% |
| Q3 2024 | 2024-09-30 | $2.3M | $1.4M | +149.17% |
| Q2 2024 | 2024-06-30 | $1.9M | $1.1M | +131.15% |
| Q1 2024 | 2024-03-31 | $781,000 | −$229,000 | −22.67% |
| Q4 2023 | 2023-12-31 | $78,000 | −$677,000 | −89.67% |
| Q3 2023 | 2023-09-30 | $905,000 | −$359,000 | −28.40% |
| Q2 2023 | 2023-06-30 | $838,000 | −$100,000 | −10.66% |
| Q1 2023 | 2023-03-31 | $1.0M | $142,000 | +16.36% |
| Q4 2022 | 2022-12-31 | $755,000 | $292,000 | +63.07% |
| Q3 2022 | 2022-09-30 | $1.3M | −$442,000 | −25.91% |
| Q2 2022 | 2022-06-30 | $938,000 | −$3.2M | −77.52% |
| Q1 2022 | 2022-03-31 | $868,000 | −$6.1M | −87.46% |
| Q4 2021 | 2021-12-31 | $463,000 | −$10.2M | −95.68% |
| Q3 2021 | 2021-09-30 | $1.7M | $1.4M | +403.24% |
| Q2 2021 | 2021-06-30 | $4.2M | $3.5M | +550.86% |
| Q1 2021 | 2021-03-31 | $6.9M | $5.9M | +572.14% |
| Q4 2020 | 2020-12-31 | $10.7M | $10.2M | +2041.40% |
| Q3 2020 | 2020-09-30 | $339,000 | −$1.0M | −74.81% |
| Q2 2020 | 2020-06-30 | $641,000 | $222,000 | +52.98% |
| Q1 2020 | 2020-03-31 | $1.0M | $764,000 | +287.22% |
| Q4 2019 | 2019-12-31 | $500,000 | $480,000 | +2400.00% |
| Q3 2019 | 2019-09-30 | $1.3M | $1.1M | +579.80% |
| Q2 2019 | 2019-06-30 | $419,000 | $342,000 | +444.16% |
| Q1 2019 | 2019-03-31 | $266,000 | $189,000 | +245.45% |
| Q4 2018 | 2018-12-31 | $20,000 | −$158,000 | −88.76% |
| Q3 2018 | 2018-09-30 | $198,000 | −$356,000 | −64.26% |
| Q2 2018 | 2018-06-30 | $77,000 | −$65,000 | −45.77% |
| Q1 2018 | 2018-03-31 | $77,000 | −$615,000 | −88.87% |
| Q4 2017 | 2017-12-31 | $178,000 | −$516,000 | −74.35% |
| Q3 2017 | 2017-09-30 | $554,000 | −$1.2M | −67.58% |
| Q2 2017 | 2017-06-30 | $142,000 | −$1.4M | −90.65% |
| Q1 2017 | 2017-03-31 | $692,000 | −$452,000 | −39.51% |
| Q4 2016 | 2016-12-31 | $694,000 | −$743,000 | −51.70% |
| Q3 2016 | 2016-09-30 | $1.7M | $1.5M | +627.23% |
| Q2 2016 | 2016-06-30 | $1.5M | $117,000 | +8.35% |
| Q1 2016 | 2016-03-31 | $1.1M | $235,000 | +25.85% |
| Q4 2015 | 2015-12-31 | $1.4M | −$47,000 | −3.17% |
| Q3 2015 | 2015-09-30 | $235,000 | −$1.1M | −82.67% |
| Q2 2015 | 2015-06-30 | $1.4M | −$1.3M | −49.05% |
| Q1 2015 | 2015-03-31 | $909,000 | −$904,000 | −49.86% |
| Q4 2014 | 2014-12-31 | $1.5M | −$397,000 | −21.11% |
| Q3 2014 | 2014-09-30 | $1.4M | $703,000 | +107.66% |
| Q2 2014 | 2014-06-30 | $2.8M | $2.5M | +1185.05% |
| Q1 2014 | 2014-03-31 | $1.8M | $1.1M | +159.74% |
| Q4 2013 | 2013-12-31 | $1.9M | $1.1M | +146.53% |
| Q3 2013 | 2013-09-30 | $653,000 | $271,000 | +70.94% |
| Q2 2013 | 2013-06-30 | $214,000 | −$628,000 | −74.58% |
| Q1 2013 | 2013-03-31 | $698,000 | $301,000 | +75.82% |
| Q4 2012 | 2012-12-31 | $763,000 | $84,000 | +12.37% |
| Q3 2012 | 2012-09-30 | $382,000 | $99,000 | +34.98% |
| Q2 2012 | 2012-06-30 | $842,000 | $348,000 | +70.45% |
| Q1 2012 | 2012-03-31 | $397,000 | $177,000 | +80.45% |
| Q4 2011 | 2011-12-31 | $679,000 | — | — |
| Q3 2011 | 2011-09-30 | $283,000 | −$189,000 | −40.04% |
| Q2 2011 | 2011-06-30 | $494,000 | — | — |
| Q1 2011 | 2011-03-31 | $220,000 | — | — |
| Q3 2010 | 2010-09-30 | $472,000 | — | — |
Standard Biotools capital expenditures (capex) trends
Over the last five fiscal years, Standard Biotools's capital expenditures (capex) decreased from $12.7M to $8.3M, a change of −$4.4M. The latest reported quarter, Q2 2026, shows $344,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Standard Biotools source filings ↗